This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...
Researchers will join a new NIH-supported network working to develop novel approach methodologies that complement or replace animal testing ...
Session Type: Oral presentation Presenter: Benjamin Kaffenberger, MD Time: March 28, 2026, 2:24-2:36 PM MT Location: Bellco Theatre 3 ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026--2036), mainly attributed to the increasing prevalence of NMOSD, ...
Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...
Kentuckians deserve confidence that every public dollar invested in addiction treatment is spent wisely, transparently and in ...
The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026-2036), mainly attributed to the increasing prevalence of ...
TEMPO.CO, Jakarta - Research results show the benefits of using supplement products in helping maintain the body's immune ...
Influencers say the ancient herb can calm nerves, improve gains, and maybe even boost testosterone. Experts weigh in on ...
India faces a growing burden of lifestyle-related digestive and metabolic disorders, says the healthcare startup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results